Myriad Genetics, Inc. (MYGN)
| Previous close | 19.97 |
| Open | 19.96 |
| Bid | 19.62 x 100 |
| Ask | 20.11 x 100 |
| Day's range | 19.70 - 20.15 |
| 52-week range | 13.82 - 24.21 |
| Volume | |
| Avg. volume | 658,383 |
| Market cap | 1.797B |
| Beta (5Y monthly) | 1.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.18 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.91 |
GlobeNewswireMyriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
SALT LAKE CITY, May 07, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align company resources to its domestic opportunities while continuing to serve key biopharma partners and patients outside the United States. As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French gro
Simply Wall St.Myriad Genetics (NASDAQ:MYGN) shareholders have endured a 26% loss from investing in the stock five years ago
Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results...
- GlobeNewswire
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
Management will also participate in four upcoming investor healthcare conferencesSALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the com
